Acrivon Therapeutics announced positive Phase 2b clinical data for ACR-368 in endometrial cancer.
Initial data from ACR-2316 Phase 1 study showed favorable tolerability and tumor shrinkage in multiple tumor types.
ACR-6840, a potential CDK11 inhibitor, selected as the next development candidate.
Positive Phase 2b Data for ACR-368
ACR-368 showed a 39% overall response rate in endometrial cancer patients with ≥2 prior lines of therapy.
ACR-2316 Phase 1 Study Update
Favorable tolerability and tumor shrinkage observed in subjects receiving ACR-2316, a WEE1/PKMYT1 inhibitor.
ACR-6840 Development
ACR-6840, a CDK11 inhibitor, nominated as the next preclinical development candidate.
- Promising response rates in endometrial cancer patients with ACR-368.
- Encouraging results in multiple tumor types with ACR-2316.
- Potential of ACR-6840 as a first-in-class CDK11 inhibitor.
Acrivon Therapeutics is making significant progress in its pipeline with positive clinical data and the nomination of a new development candidate. The company's focus on precision medicines for high-value opportunities shows promise for future growth and innovation.